OpGen

The infectious disease molecular testing firm acquired AdvanDx and went public in the fiscal year. However, full-year revenues fell 23 percent.

The DC Department of Health and District of Columbia Hospital Association are tracking the prevalence of carbapenem-resistant Enterobacteriaceae in healthcare facilities.

Revenues for the quarter rose about 18 percent compared to revenues for the same quarter in 2014.

Revenues for the quarter dropped percent to $375,146 from $1.1 million in the same quarter in 2014.

The acquisition will provide OpGen with FDA-approved and CE-marked tests for use with its MDRO Gene tests and bioinformatics for multidrug-resistant organisms.

The partners will work together to build products based on Fluidigm's Juno and Biomark technology under the five-year deal.

Revenues for the quarter dropped about 55 percent compared to revenues for the same quarter in 2014.

The microbial genetics analysis firm went public today offering 2.85 million units for $17.1 million in gross proceeds.

The company plans to offer 3.75 million shares of its stock at $8 to $10 per share, and anticipates listing on the Nasdaq under ticker symbol "OPGN."